

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:42

First Dose M/F: NA / NA

Lab: MBA

C Number: C97011A
Lock Date: 09/18/2000
Cage Range: All
Date Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: All
Study Gender: Both
PWG Approval Date: NONE

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:42
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	90 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Natural Death		1
Survivors		
Accidentally Killed	4	
Natural Death		1
Terminal Sacrifice	11	13
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(15)
Salivary Glands	(15)	(15)
Stomach, Forestomach	(15)	(14)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(14)
Adenoma		1 (7%)
Adrenal Medulla	(15)	(14)
Pituitary Gland	(14)	(14)
Thyroid Gland	(14)	(14)
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Epididymis	(15)	(14)
Prostate	(0)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 97011-15

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:42

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	90 MG/KG
Seminal Vesicle	(0)	(6)
Testes	(15)	(15)
HEMATOPOIETIC SYSTEM		
Bone Marrow	(15)	(14)
Lymph Node, Mandibular	(15)	(14)
Lymph Node, Mediastinal	(10)	(9)
Lymph Node, Mesenteric	(15)	(13)
Spleen	(15)	(14)
Thymus	(15)	(13)
INTEGUMENTARY SYSTEM		
Mammary Gland	(2)	(0)
Skin	(15)	(15)
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		
Peripheral Nerve	(15)	(15)
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Alveolar/Bronchiolar Adenoma	3 (20%)	
Alveolar/Bronchiolar Carcinoma	1 (7%)	
SPECIAL SENSES SYSTEM		
None		
URINARY SYSTEM		
Kidney	(15)	(14)
Urinary Bladder	(14)	(14)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 97011-15

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:42

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse MALE

VEHICLE CONTROL

90 MG/KG

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:42
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse MALE	VEHICLE CONTROL	90 MG/KG
Tumor Summary for MALE		
Total Animals with Primary Neoplasms (b)	3	1
Total Primary Neoplasms	4	1
Total Animals with Benign Neoplasms	3	1
Total Benign Neoplasms	3	1
Total Animals with Malignant Neoplasms	1	
Total Malignant Neoplasms	1	
Total Animals with Metastatic Neoplasms		
Total Metastatic Neoplasms		
Total Animals with Malignant Neoplasms Uncertain Primary Site		
Total Animals with Neoplasms Uncertain - Benign or Malignant		
Total Uncertain Neoplasms		

END OF MALE DATA

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:42
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	90 MG/KG
Disposition Summary		
Animals Initially In Study	15	15
Early Deaths		
Accidentally Killed	1	
Moribund Sacrifice		1
Survivors		
Accidentally Killed	2	
Terminal Sacrifice	12	14
Animals Examined Microscopically	15	15
ALIMENTARY SYSTEM		
Liver	(15)	(15)
Salivary Glands	(15)	(15)
Stomach, Forestomach	(15)	(15)
CARDIOVASCULAR SYSTEM		
None		
ENDOCRINE SYSTEM		
Adrenal Cortex	(15)	(15)
Adrenal Medulla	(15)	(15)
Pituitary Gland	(13)	(12)
Thyroid Gland	(15)	(15)
GENERAL BODY SYSTEM		
None		
GENITAL SYSTEM		
Ovary	(15)	(14)
Uterus	(15)	(15)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 97011-15

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:42

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	90 MG/KG
HEMATOPOIETIC SYSTEM		
Bone Marrow	(15)	(15)
Lymph Node	(1)	(0)
Lymph Node, Mandibular	(15)	(15)
Lymph Node, Mediastinal	(11)	(12)
Lymph Node, Mesenteric	(15)	(15)
Spleen	(15)	(15)
Thymus	(15)	(14)
INTEGUMENTARY SYSTEM		
Mammary Gland	(14)	(14)
Skin	(15)	(15)
MUSCULOSKELETAL SYSTEM		
None		
NERVOUS SYSTEM		
Brain	(1)	(0)
Peripheral Nerve	(15)	(15)
Spinal Cord	(1)	(0)
RESPIRATORY SYSTEM		
Lung	(15)	(15)
Alveolar/Bronchiolar Adenoma	1 (7%)	2 (13%)
Alveolar/Bronchiolar Adenoma, Multiple		1 (7%)
SPECIAL SENSES SYSTEM		
None		
URINARY SYSTEM		
Kidney	(15)	(15)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 97011-15

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/FVB/N

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014

Time Report Requested: 05:31:42

First Dose M/F: NA / NA

Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	90 MG/KG
Urinary Bladder	(15)	(15)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically

Experiment Number: 97011-15
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: Mouse/FVB/N

P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)

Test Compound: Transgenic model evaluation (Cyclophosphamide monohydrate)

CAS Number: 6055-19-2

Date Report Requested: 10/23/2014
Time Report Requested: 05:31:42
First Dose M/F: NA / NA
Lab: MBA

FVB/N Mouse FEMALE	VEHICLE CONTROL	90 MG/KG
Tumor Summary for FEMALE		
Total Animals with Primary Neoplasms (b)	1	3
Total Primary Neoplasms	1	3
Total Animals with Benign Neoplasms	1	3
Total Benign Neoplasms	1	3
Total Animals with Malignant Neoplasms		
Total Malignant Neoplasms		
Total Animals with Metastatic Neoplasms		
Total Metastatic Neoplasms		
Total Animals with Malignant Neoplasms Uncertain Primary Site		
Total Animals with Neoplasms Uncertain - Benign or Malignant		
Total Uncertain Neoplasms		

**** END OF REPORT ****

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

* Number of animals with any tissue examined microscopically